Charles River Laboratories (CRL) Tops Q3 EPS by 8c; Narrows Outlook

Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $1.30, $0.08 better than the analyst estimate of $1.22. Revenue for the quarter came in at $464.2 million versus the consensus estimate of $458.72 million.

GUIDANCE:

Charles River Laboratories sees FY2017 EPS of $5.08-$5.18, versus prior $5.00-$5.15 and the consensus of $5.10.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• Charles River Leverages Expertise in Rapid and In Vitro Methods to Reduce Cell Banking Timelines
• Forgent Power Solutions, Inc. (FPS) Tops Q2 EPS by 1c, Beats on Revenue; Offers FY27 Guidance